Literature DB >> 8410981

Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.

M E Wall1, M C Wani, A W Nicholas, G Manikumar, C Tele, L Moore, A Truesdale, P Leitner, J M Besterman.   

Abstract

A large number of camptothecin (CPT) analogs have been prepared in the 20S, 20RS, and 20R configurations with a number of ring A substituents. Topoisomerase I (T-I) inhibition data (IC50) have been obtained by standard procedures. In general, substitution at the 9 or 10 positions with amino, halogeno, or hydroxyl groups in compounds with 20S configuration results in compounds with enhanced T-I inhibition. Compounds in the 20RS configuration were less active in vitro and in vivo and those in the 20R configuration were inactive. Compounds with 10,11-methylenedioxy substitution on ring A displayed a marked increase in potency in the T-I inhibition assay. The activities of some of the analogs as determined in a variety of in vivo assays including the L-1210 mouse leukemia assay were, in general, in accord with T-I inhibition. A number of water-soluble analogs such as 20-glycinate esters, 9-glycinamides, or hydrolyzed lactone salts were prepared and tested in in vitro and in vivo assays. In general, these compounds were less active than CPT both in terms of T-I inhibition and life prolongation in the L-1210 assay. However, certain 20-glycinate esters showed good in vivo activity after iv administration.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410981     DOI: 10.1021/jm00070a013

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  Multiple event activation of a generic prodrug trigger by antibody catalysis.

Authors:  D Shabat; C Rader; B List; R A Lerner; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

2.  MM3(96) parameterization for camptothecin analogs: an ab initio and molecular mechanics study.

Authors:  S W Carrigan; J H Lii; J P Bowen
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

3.  Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents.

Authors:  S W Carrigan; P C Fox; M E Wall; M C Wani; J P Bowen
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

4.  Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor.

Authors:  Yakun Chen; Yong Tang; Gregory T Robbins; Daotai Nie
Journal:  J Pharmacol Exp Ther       Date:  2010-05-26       Impact factor: 4.030

Review 5.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

6.  Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.

Authors:  Maris A Cinelli; Andrew Morrell; Thomas S Dexheimer; Evan S Scher; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2008-07-17       Impact factor: 7.446

7.  Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.

Authors:  Katherine E Peterson; Maris A Cinelli; Andrew E Morrell; Akhil Mehta; Thomas S Dexheimer; Keli Agama; Smitha Antony; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-06-28       Impact factor: 7.446

8.  Layer-by-layer nanoencapsulation of camptothecin with improved activity.

Authors:  Gaurav Parekh; Pravin Pattekari; Chaitanya Joshi; Tatsiana Shutava; Mark DeCoster; Tatyana Levchenko; Vladimir Torchilin; Yuri Lvov
Journal:  Int J Pharm       Date:  2014-02-06       Impact factor: 5.875

9.  Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide.

Authors:  Wei Feng; Mavurapu Satyanarayana; Yuan-Chin Tsai; Angela A Liu; Leroy F Liu; Edmond J LaVoie
Journal:  Eur J Med Chem       Date:  2009-02-20       Impact factor: 6.514

Review 10.  Camptothecins: a review of their chemotherapeutic potential.

Authors:  Hulya Ulukan; Peter W Swaan
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.